Opus Genetics announced that the U.S. Food and Drug Administration has accepted its investigational gene therapy, OPGx‑LCA5, into the Rare Disease Evidence Principles (RDEP) program. The RDEP initiative, launched in late 2025, is designed to streamline development for ultra‑rare genetic conditions affecting fewer than 1,000 U.S. patients by enabling early collaboration on trial design and evidence generation.
LCA5 is a severe, early‑onset inherited retinal disease caused by mutations in the LCA5 gene. Estimates place the U.S. prevalence at roughly 170–200 patients, and no approved therapies exist. The disease leads to progressive vision loss that can result in blindness during childhood, creating a critical unmet medical need.
OPGx‑LCA5 already holds RMAT, Orphan Drug, and Rare Pediatric Disease designations. RDEP acceptance complements these statuses by allowing adaptive trial designs and potentially smaller, more efficient studies, which could accelerate regulatory approval and reduce development costs. The program’s collaborative framework is expected to shape the clinical development plan and may enable approval based on a single adequate and well‑controlled study supported by confirmatory evidence.
The therapy is currently being evaluated in a Phase 1/2 trial at the University of Pennsylvania. Early pediatric data from the study have shown improvements in vision, providing encouraging evidence that likely informed the FDA’s decision to include OPGx‑LCA5 in the RDEP program.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.